FOX CHASE CANCER CENTER

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Established: 1904-01-01

Employees: -

Market Cap: -

Website: http://www.foxchase.org

Clinical Trials

Observation Study of Patients With Non-Small Cell Lung Cancer and Esophageal Cancer Treated With Chemo-Radiation Followed by Surgery

Completed

Conditions: Lung Cancer
Esophageal Cancer

Interventions: Drug: Carboplatin
Drug: Paclitaxel
Radiation: Radiation Therapy

First Posted Date: 2017-03-29

Last Posted Date: 2021-10-12

Lead Sponsor: Fox Chase Cancer Center

Target Recruit Count: 6

Registration Number: NCT03095209

Locations: 🇺🇸
Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States

Pulsed Low Dose Rate Radiation With Concurrent Chemotherapy for Non-Small Cell Lung Cancer and Esophageal Cancer

Phase 1

Recruiting

Conditions: Lung Cancer
Esophageal Cancer

Interventions: Radiation: Pulsed Low Dose Radiation
Drug: Carboplatin
Drug: Paclitaxel

First Posted Date: 2017-03-29

Last Posted Date: 2023-05-23

Lead Sponsor: Fox Chase Cancer Center

Target Recruit Count: 40

Registration Number: NCT03094884

Locations: 🇺🇸
Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States

Improving the Approach to and Management of the Older Metastatic Breast Cancer Patient

Not Applicable

Completed

Conditions: Metastatic Breast Cancer

Interventions: Behavioral: Didactic session
Behavioral: Comprehensive Geriatric Assessment

First Posted Date: 2017-01-02

Last Posted Date: 2020-03-02

Lead Sponsor: Fox Chase Cancer Center

Target Recruit Count: 100

Registration Number: NCT03007641

Locations: 🇺🇸
AtlantiCare Cancer Care Institute, Egg Harbor Township, New Jersey, United States
🇺🇸
Bozeman Deaconess Hospital, Bozeman, Montana, United States
🇺🇸
Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States

and more 2 locations

Study of TAK-228 (MLN0128) in Soft Tissue Sarcomas

Phase 2

Terminated

Conditions: Soft-tissue Sarcoma

Interventions: Drug: TAK-228

First Posted Date: 2016-12-09

Last Posted Date: 2022-10-14

Lead Sponsor: Fox Chase Cancer Center

Target Recruit Count: 6

Registration Number: NCT02987959

Locations: 🇺🇸
Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States

Cystoscopic Evaluation Predicting pT0 Urothelial Carcinoma of the Bladder

Not Applicable

Active, not recruiting

Conditions: Urothelial Carcinoma

Interventions: Procedure: Radical Cystectomy

First Posted Date: 2016-11-21

Last Posted Date: 2024-06-18

Lead Sponsor: Fox Chase Cancer Center

Target Recruit Count: 65

Registration Number: NCT02968732

Locations: 🇺🇸
Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States

Phase I/II Study of Lenalidomide Plus Pembrolizumab in Patients With Solid Tumors With Expansion in Non-small Cell Lung Cancer

Phase 1

Terminated

Conditions: Relapsed or Refractory Solid Tumors
Nonsmall Cell Lung Cancer

Interventions: Drug: Lenalidomide
Drug: Pembrolizumab

First Posted Date: 2016-11-15

Last Posted Date: 2021-12-30

Lead Sponsor: Fox Chase Cancer Center

Target Recruit Count: 3

Registration Number: NCT02963610

Locations: 🇺🇸
Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States

A Study of Pembrolizumab in Patients With Neuroendocrine Tumors

Phase 2

Completed

Conditions: Neuroendocrine Tumors

Interventions: Drug: Pembrolizumab

First Posted Date: 2016-10-20

Last Posted Date: 2021-03-09

Lead Sponsor: Fox Chase Cancer Center

Target Recruit Count: 21

Registration Number: NCT02939651

Locations: 🇺🇸
Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States
🇺🇸
MD Anderson Cancer Center, Houston, Texas, United States

A Study of Pembrolizumab With Carboplatin and Gemcitabine in Patients With Metastatic Triple Negative Breast Cancer

Phase 2

Active, not recruiting

Conditions: Carcinoma Breast Stage IV

Interventions: Drug: Pembrolizumab
Drug: Carboplatin
Drug: Gemcitabine

First Posted Date: 2016-04-28

Last Posted Date: 2024-06-04

Lead Sponsor: Fox Chase Cancer Center

Target Recruit Count: 87

Registration Number: NCT02755272

Locations: 🇺🇸
Indiana University, Indianapolis, Indiana, United States
🇺🇸
Fox Chase Cancer Center - Philadelphia, Philadelphia, Pennsylvania, United States
🇺🇸
Washington University in St. Louis, Saint Louis, Missouri, United States

and more 3 locations

Pilot Study of an Intimacy Enhancement Intervention for Couples Facing Breast Cancer

Not Applicable

Completed

Conditions: Breast Cancer

Interventions: Behavioral: Intimacy Enhancing Intervention
Behavioral: Living Healthy Together
Behavioral: Partner-Assisted Coping Skills Training
Behavioral: Behavioral, Psychological or Informational Intervention

First Posted Date: 2016-03-29

Last Posted Date: 2018-10-25

Lead Sponsor: Fox Chase Cancer Center

Target Recruit Count: 89

Registration Number: NCT02721147

Locations: 🇺🇸
Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States

Risk Enabled Therapy After Initiating Neoadjuvant Chemotherapy for Bladder Cancer (RETAIN)

Phase 2

Active, not recruiting

Conditions: Urothelial Carcinoma of the Bladder

Interventions: Drug: Methotrexate
Drug: Vinblastine
Drug: Doxorubicin
Drug: Cisplatin
Radiation: Intensity modulated radiation therapy (IMRT)
Procedure: Transurethral Resection of Bladder tumor
Drug: 5-FU
Drug: Mitomycin C

First Posted Date: 2016-03-17

Last Posted Date: 2023-12-11

Lead Sponsor: Fox Chase Cancer Center

Target Recruit Count: 78

Registration Number: NCT02710734

Locations: 🇺🇸
Johns Hopkins, Baltimore, Maryland, United States
🇺🇸
Sidney kimmel Cancer Center, Philadelphia, Pennsylvania, United States
🇺🇸
Washington Cancer Institute at MedStar Washington Hospital Center, Washington, District of Columbia, United States

and more 1 locations

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy